Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Lung Neoplasms 1Lung Diseases 1Carcinoma 1Bronchial Neoplasms 1

Interventions

pembrolizumab 64Cisplatin 44Cetuximab 26Carboplatin 25Paclitaxel 19Magnetic Resonance Spectroscopy 19Radiotherapy, Intensity-Modulated 17Nivolumab 17Radiotherapy 16Specimen Handling 15Docetaxel 14Platinum 131,2-diaminocyclohexaneplatinum II citrate 12Taxes 8Fluorouracil 8Biopsy 8atezolizumab 6Radiation 6(225)Ac-DOTA-c(RGDyK) 6dostarlimab 5cemiplimab 5Ipilimumab 5Immunoglobulin G 5Cyclophosphamide 5Surgical Procedures, Operative 4Standard of Care 4Immune Checkpoint Inhibitors 4Disulfides 4Bevacizumab 4Albumin-Bound Paclitaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × Toll-Like Receptor 1 × 90 days × Clear all
NCT03645928 2026-05-15

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Iovance Biotherapeutics, Inc.

Phase 2 Terminated
225 enrolled
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡